ID: ALA1170182

Max Phase: Preclinical

Molecular Formula: C13H23N

Molecular Weight: 193.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC1(N)C2CC3CC(C2)CC1C3

Standard InChI:  InChI=1S/C13H23N/c1-2-3-13(14)11-5-9-4-10(7-11)8-12(13)6-9/h9-12H,2-8,14H2,1H3

Standard InChI Key:  AXUITRIGTVUAOK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 193.33

Molecular Weight (Monoisotopic): 193.1830

AlogP: 2.94

#Rotatable Bonds: 2

Polar Surface Area: 26.02

Molecular Species: BASE

HBA: 1

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 1

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 10.84

CX LogP: 2.80

CX LogD: -0.09

Aromatic Rings: 0

Heavy Atoms: 14

QED Weighted: 0.72

Np Likeness Score: 0.77

References

1. Eleftheratos S, Spearpoint P, Ortore G, Kolocouris A, Martinelli A, Martin S, Hay A..  (2010)  Interaction of aminoadamantane derivatives with the influenza A virus M2 channel-docking using a pore blocking model.,  20  (14): [PMID:20570509] [10.1016/j.bmcl.2010.05.049]

2. Kolocouris A, Tzitzoglaki C, Johnson FB, Zell R, Wright AK, Cross TA, Tietjen I, Fedida D, Busath DD..  (2014)  Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.,  57  (11): [PMID:24793875] [10.1021/jm500598u]

3. Tzitzoglaki C, Wright A, Freudenberger K, Hoffmann A, Tietjen I, Stylianakis I, Kolarov F, Fedida D, Schmidtke M, Gauglitz G, Cross TA, Kolocouris A..  (2017)  Binding and Proton Blockage by Amantadine Variants of the Influenza M2WT and M2S31N Explained.,  60  (5): [PMID:28107633] [10.1021/acs.jmedchem.6b01115]

Source

Source(1):

• Scientific Literature